1. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 1998;59:65–73.
2. De Jonge E, Levi M, Stoutenbeek CP, Van Deventer SJH. Current drug treatment strategies for disseminated intravascular coagulation. Drugs 1998;55:767–77.
3. Baker WF Jr. Clinical aspects of disseminated intravascular coagulation: a clinician’s point of view. Sem Thrombosis Hemostasis 1989;15:1–57.
4. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586–92.
5. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016;2:16037.
6. Kolev K, Longstaff C. Bleeding related to disturbed fibrinolysis. Br J Haematol 2016;175:12–23.
7. Sharma S, Mayberry JC, DeLoughery TG, Mullins RJ. Fatal cerebroembolism from nonbacterial thrombotic endocarditis in a trauma patient: case report and review. Mil Med 2000;165:83–5.
8. Toh CH, Alhamdi Y, Abrams ST. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation. Ann Lab Med 2016;36:505–12.
9. Yu M, Nardella A, Pechet L. Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis. Crit Care Med 2000;28:1777–80.
10. Mant MJ, King EG. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance, and therapy based on 47 patients. Am J Med 1979;67:557–63.
11. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24–33.
12. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191–5.
13. Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol 2016;174:503–14.
14. Gonzalez E, Moore EE, Moore HB. Management of trauma-induced coagulopathy with thrombelastography. Crit Care Clin 2017;33:119–34.
15. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–35.
16. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223–9.
17. Murrin RJ, Murray JA. Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev 2006;20:51–60.
18. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017;129:2836–46.
19. Patton JF, Manning KR, Case D, Owen J. Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol 1994;47:94–9.
20. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393–7.
21. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpurahemolytic uremic syndrome—clinical experience in 108 patients. N Engl J Med 1991;325:398–403.
22. Kaplan BS, Trachtman H. Improve survival with plasma exchange thrombotic thrombopenic purpura-hemolytic uremic syndrome. Am J Med 2001;110:156–7.
23. Kremer Hovinga JA, Coppo P, Lammle B, et al. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017;3:17020.
24. Asherson RA. The catastrophic antiphospholipid syndrome [editorial]. J Rheumatol 1992;19:508–12.
25. Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 1996;5:414–7.
26. Asherson RA, Cervera R. Castastrophic antiphospholipid syndrome. Curr Opinion Hematol 2000;5:325–9.
27. Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rhuem 2006;2:81–9.
28. Rodriguez-Pinto I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: The current management approach. Best Pract Res Clin Rheumatol 2016;30:239–9.
29. Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol 2016;28:218–27.
30. Hoffman JN, Faist E. Coagulation inhibitor replacement during sepsis: useless? Crit Care Med 2000;28(9 Suppl):S74–6.
31. Wada H, Asakura H, Okamoto K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Thromb Res 2010;125:6–11.
32. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982;60:284–7.
33. Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979;190:91–9.
34. Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth 2000;85:487–91.
35. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409–17.
36. Blair SD, Janvrin SB, McCollum CN, Greenhalgh RM. Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg 1986;73:783–5.
37. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11–21.
38. Miller RD, Robbins TO, Tong MJ, Barton SL. Coagulation defects associated with massive blood transfusions. Ann Surg 1971;174:794–801.
39. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987;67:365–8.
40. Chowdhury P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004;125:69–73.
41. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982;60:284–7.
42. Callander N, Rapaport SI. Trousseau’s syndrome. West J Med 1993;158:364–71.
43. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104–9.
44. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782–8.
45. Yoshikawa T, Tanaka KR, Guze LB. Infection and disseminated intravascular coagulation. Medicine (Baltimore) 1971;50:237–58.
46. Jagneaux T, Taylor DE, Kantrow SP. Coagulation in sepsis. Am J Med Sci 2004;328:196–204.
47. Lipinska-Gediga M. Coagulopathy in sepsis - a new look at an old problem. Anaesthesiol Intensive Ther 2016;48:352–9.
48. Van Gorp ECM, Suharti C, ten Cate H, et al. Review: Infections diseases and coagulation disorders. Journal of Infectious Diseases 1999;180:176–86.
49. McDonald B, Davis RP, Kim SJ, et al. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood 2017;129:1357–67.
50. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011;118:1952–61.
51. Darmstadt GL. Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol 1998;15:169–83.
52. Davis MD, Dy KM, Nelson S. Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic. J Am Acad Dermatol 2007;57:944–56.
53. Spicer TE, Rau JM. Purpura fulminans. Am J Med 1976;61:566–71.
54. Josephson C, Nuss R, Jacobson L, et al. The varicellaautoantibody syndrome. Pediatr Res 2001;50:345–52.
55. Smith OP, White B. Infectious purpura fulminans: diagnosis and treatment. Br J Haematol 1999;104:202–7.
56. Gamper G, Oschatz E, Herkner H, et al. Sepsis-associated purpura fulminans in adults. Wien Klin Wochenschr 2001;113:107–12.
57. Ward KM, Celebi JT, Gmyrek R, Grossman ME. Acute infectious purpura fulminans associated with asplenism or hyposplenism. J Am Acad Dermatol 2002;47:493–6.
58. Childers BJ, Cobanov B. Acute infectious purpura fulminans: a 15-year retrospective review of 28 consecutive cases. Am Surg 2003;69:86–90.
59. Carpenter CT, Kaiser AB. Purpura fulminans in pneumococcal sepsis: case report and review. Scand J Infect Dis 1997;29:479–83.
60. Warkentin TE, Pai M. Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is ‘shock liver’ the unrecognized provocateur of ischemic limb necrosis: reply. J Thromb Haemost 2016;14:2317–9.
61. Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med 2015;373:642–55.
62. Duncan A. New therapies for severe meningococcal disease but better outcomes? Lancet 1997;350:1565–6.
63. Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet1997;350:1590–3.
64. Branson HE, Katz J. A structured approach to the management of purpura fulminans. J Natl Med Assoc 1983;75:821–5.
65. Nolan J, Sinclair R. Review of management of purpura fulminans and two case reports. Br J Anaesth 2001;86:581–6.
66. Manios SG, Kanakoudi F, Maniati E. Fulminant meningococcemia. Heparin therapy and survival rate. Scand J Infect Dis 1971;3:127–33.
67. Giudici D, Baudo F, Palareti G, et al. Antithrombin replacement in patients with sepsis and septic shock. Haematologica 1999;84:452–60.
68. Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. Crit Care Med 2000;28(9 Suppl):S38–43.
69. Levi M, De Jonge E, van der PT, ten Cate H. Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med 2000;28(9 Suppl):S20–4.
70. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126:646–52.
71. White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000;96:3719–24.
72. Schellongowski P, Bauer E, Holzinger U, et al. Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin). Vox Sang 2006;90:294–301.
73. DeLoughery TG. Coagulation defects in trauma patients: etiology, recognition, and therapy. Crit Care Clin 2004;20:13–24.
74. Cohen MJ, Christie SA. Coagulopathy of trauma. Crit Care Clin 2017;33:101–18.
75. Giordano S, Spiezia L, Campello E, Simioni P. The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. Intern Emerg Med 2017 May 5.
76. Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of trauma-induced coagulopathy. Blood 2016;128:1043–9.
77. Eddy VA, Morris JA Jr, Cullinane DC. Hypothermia, coagulopathy, and acidosis. Surg Clin North Am 2000;80:845–54.
78. Peng RY, Bongard FS. Hypothermia in trauma patients. J Am Coll Surg 1999;188:685–96.
79. Steinemann S, Shackford SR, Davis JW. Implications of admission hypothermia in trauma patients. J Trauma 1990;30:200–2.
80. Rajek A, Greif R, Sessler DI, et al. Core cooling by central venous infusion of ice-cold (4 degrees C and 20 degrees C) fluid: isolation of core and peripheral thermal compartments. Anesthesiol 2000;93:629–37.
81. Watts DD, Trask A, Soeken K, et al. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma 1998;44:846–54.
82. Ferrara A, MacArthur JD, Wright HK, et al. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg 1990;160:515–8.
83. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015;313:471–82.
84. Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski SR, Holcomb JB. How I treat patients with massive hemorrhage. Blood 2014;124:3052–8.
85. Stone HH, Strom PR, Mullins RJ. Management of the major coagulopathy with onset during laparotomy. Ann Surg 1983;197:532–5.
86. WOMAN Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32.
87. Hall DR. Abruptio placentae and disseminated intravascular coagulopathy. Semin Perinatol 2009;33:189–95.
88. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009;23:167–76.
89. Collins P, Abdul-Kadir R, Thachil J, Subcommittees on Women’ s Health Issues in T, Haemostasis, on Disseminated Intravascular C. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:205–10.
90. Baxter JK, Weinstein L. HELLP syndrome: the state of the art. Obstet Gynecol Surv 2004;59:838–45.
91. Egerman RS, Sibai BM. HELLP syndrome. Clin Obstetr Gynecol 1999;42:381–9.
92. Saphier CJ, Repke JT. Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a review of diagnosis and management. Sem Perinatol 1998;22:118–33.
93. Le Thi TD, Tieulie N, Costedoat N, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005;64:273–8.
94. Martin JN Jr, Perry KG Jr, Blake PG, et al. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. Am J Obstet Gynecol 1997;177:1011–7.
95. Magann EF, Martin JN Jr. Twelve steps to optimal management of HELLP syndrome. Clinical Obstet Gynecol 1999;42:532–50.
96. Jwayyed SM, Blanda M, Kubina M. Acute fatty liver of pregnancy. J Emerg Medi 1999;17:673–7.
97. Bacq Y. Acute fatty liver of pregnancy. Sem Perinatol 1998;22:134–40.
98. Egerman RS, Sibai BM. Imitators of preeclampsia and eclampsia. Clin Obstet Gynecol 1999;42:551–62.
99. Garratty G. Immune cytopenia associated with antibiotics. Transfusion Medi Rev 1993;7:255–67.
100. Chenoweth CE, Judd WJ, Steiner EA, Kauffman CA. Cefotetan-induced immune hemolytic anemia. Clin Infect Dis 1992;15:863–5.
101. Garratty G, Nance S, Lloyd M, Domen R. Fatal immune hemolytic anemia due to cefotetan. Transfusion 1992;32:269–71.
102. Endoh T, Yagihashi A, Sasaki M, Watanabe N. Ceftizoxime-induced hemolysis due to immune complexes:case report and determination of the epitope responsible for immune complex-mediated hemolysis. Transfusion 1999;39:306–9.
103. Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion 1999;39:1239–46.
104. Martin ME, Laber DA. Cefotetan-induced hemolytic anemia after perioperative prophylaxis. Am J Hematol 2006;81:186–8.
105. Bernini JC, Mustafa MM, Sutor LJ, Buchanan GR. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J Pediatr 1995;126:813–5.
106. Borgna-Pignatti C, Bezzi TM, Reverberi R. Fatal ceftriaxone-induced hemolysis in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1995;14:1116–7.
107. Lascari AD, Amyot K. Fatal hemolysis caused by ceftriaxone. J Pediatr 1995;126:816–7.
108. Gottschall JL, Elliot W, Lianos E, et al. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood 1991;77:306–10.
109. Gottschall JL, Neahring B, McFarland JG, et al. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994;47:283–9.
110. Crum NF, Gable P. Quinine-induced hemolytic-uremic syndrome. South Med J 2000;93:726–8.
111. Vesely T, Vesely JN, George JN. Quinine-Induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): frequency, clinical features, and long-term outcomes. Blood 2000;96:629 [abstract].
112. Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau’s syndrome. Devastating coagulopathy in the absence of heparin. Am J Med 1985;79:423–30.
113. Sack GH, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinic, pathophysiologic, and therapeutic features. Medicine 1977;56:1–37.
114. Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723–9.
115. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401–10.
116. de la Fouchardiere C, Flechon A, Droz JP. Coagulopathy in prostate cancer. Neth J Med 2003;61:347–54.
117. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133(6 Suppl):454S–545S.
118. Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677–86.
119. Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol 2012;87:596–603.
120. Cao M, Li T, He Z, et al. Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia. Blood 2017;129:1855–64.
121. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505–15.
122. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111–21.
123. Dombret H, Scrobohaci ML, Ghorra P, et al. Coagulation disorders associated iwth acute promyelocytic leukemia: Corrective effect of all-trans retinoic acid treatment. Leukemia 1993;7:2–9.
124. Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007;2007:165–71
125. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009;114:5126–35.
126. Sanz MA, Grimwade D, Tallman MS, et al. Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–91.
127. Lu Q, Clemetson JM, Clemetson KJ. Snake venoms and hemostasis. J Thromb Haemost 2005;3:1791–9.
128. Berling I, Isbister GK. Hematologic effects and complications of snake envenoming. Transfus Med Rev 2015;29:82–9.
129. Isbister GK, Jayamanne S, Mohamed F, et al. A randomized controlled trial of fresh frozen plasma for coagulopathy in Russell’s viper (Daboia russelii ) envenoming. J Thromb Haemost 2017;15:645–54.
130. Rodriguez V, Lee A, Witman PM, Anderson PA. Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol 2009;31:522–6.
131. Triana P, Dore M, Cerezo VN, et al. Sirolimus in the treatment of vascular anomalies. Eur J Pediatr Surg 2017;27:86–90.
